1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
656222C427F81D1CB652579DE00341EFB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/56222C427F81D1CB652579DE00341EFB!OpenDocument
18
19OpenDocument
2035.172.224.102
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Medical Affairs Health Economics Outcomes Research Organizational Reporting and Structure

Complimentary Excerpt: Risk Mitigation Excellence: Resources and Trends for REMS & RMP Programs

DB Image

Excerpt in Cart

ID: MD-315


Features:

13 Info Graphics

16 Data Graphics

80 Metrics

6 Narratives


Pages/Slides: 4


Published: Pre-2017


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click
"Download Free Excerpt".


To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5203 "Risk Mitigation Excellence: Resources and Trends for REMS & RMP Programs."


Industries Profiled:
Medical Device; Pharmaceutical; Biotech; Chemical; Consumer Products; Diagnostic; Health Care


Companies Profiled:
Baxter International; Genericon Pharma; Actelion; MannKind Corporation; Bristol-Myers Squibb; Genentech; Roche; Bayer Healthcare; Cephalon; AstraZeneca; Inc.; Johnson & Johnson; Pfizer; Covidien; Amylin; Abbott; Upsher-Smith; Merz Pharma; Teva Pharmaceutical Industries Ltd; Ipsen

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.